These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24448702)

  • 1. The diagnosis of thoracic malignant mesothelioma: practical considerations and recent developments.
    Smith M; Colby T
    Turk Patoloji Derg; 2014; 30(1):1-10. PubMed ID: 24448702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary pleural epithelioid mesothelioma of clear cell type: a case report and review of current literature.
    Gkogkou C; Samitas K; Foteinou M
    Ultrastruct Pathol; 2011 Dec; 35(6):267-70. PubMed ID: 21978187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Suster S; Moran CA
    Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases.
    Weissferdt A; Kalhor N; Suster S
    Ann Diagn Pathol; 2011 Feb; 15(1):25-9. PubMed ID: 21106421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
    Lagana SM; Taub RN; Borczuk AC
    Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelioid angiosarcoma at chest wall which needs to be carefully distinguished from malignant mesothelioma: report of a rare case.
    Fan C; Liu Y; Lin X; Han Y; He A; Wang E
    Int J Clin Exp Pathol; 2014; 7(12):9056-60. PubMed ID: 25674287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
    Moran CA; Wick MR; Suster S
    Semin Diagn Pathol; 2000 Aug; 17(3):178-83. PubMed ID: 10968703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
    Bahrami A; Allen TC; Cagle PT
    Pathol Int; 2008 Nov; 58(11):730-4. PubMed ID: 18844940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.
    Leong AS; Stevens MW; Mukherjee TM
    Semin Diagn Pathol; 1992 May; 9(2):141-50. PubMed ID: 1609156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
    Ordóñez NG
    Hum Pathol; 2013 Jan; 44(1):1-19. PubMed ID: 22963903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
    Galateau-Salle F
    Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
    Rakha EA; Patil S; Abdulla K; Abdulkader M; Chaudry Z; Soomro IN
    Diagn Cytopathol; 2010 Dec; 38(12):874-9. PubMed ID: 20049969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease: a distinctive variant of mesothelioma.
    Larsen BT; Klein JR; Hornychová H; Nuti R; Thirumala S; Leslie KO; Colby TV; Tazelaar HD
    Am J Surg Pathol; 2013 Oct; 37(10):1555-64. PubMed ID: 23797722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
    Jo VY; Cibas ES; Pinkus GS
    Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J; Lamerz R; Permanetter W
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
    Sherman ME; Mark EJ
    Arch Pathol Lab Med; 1990 Aug; 114(8):845-51. PubMed ID: 2375659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.